218 related articles for article (PubMed ID: 26571227)
1. Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving.
Jáuregui I; Ramaekers JG; Yanai K; Farré M; Redondo E; Valiente R; Labeaga L
Expert Opin Drug Saf; 2016 Jan; 15(1):89-98. PubMed ID: 26571227
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of bilastine: 2nd generation H1-antihistamines.
Scaglione F
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1999-2005. PubMed ID: 23242729
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria.
Church MK
Expert Opin Drug Saf; 2011 Sep; 10(5):779-93. PubMed ID: 21831011
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria.
Rodríguez M; Vozmediano V; García-Bea A; Novák Z; Yáñez A; Campo C; Labeaga L
Eur J Pediatr; 2020 May; 179(5):801-805. PubMed ID: 31919579
[TBL] [Abstract][Full Text] [Related]
5. Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers.
Farré M; Pérez-Mañá C; Papaseit E; Menoyo E; Pérez M; Martin S; Bullich S; Rojas S; Herance JR; Trampal C; Labeaga L; Valiente R
Br J Clin Pharmacol; 2014 Nov; 78(5):970-80. PubMed ID: 24833043
[TBL] [Abstract][Full Text] [Related]
6. Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients.
Demonte A; Guanti MB; Liberati S; Biffi A; Fernando F; Fainello M; Pepe P
Eur Rev Med Pharmacol Sci; 2018 Feb; 22(3):820-828. PubMed ID: 29461615
[TBL] [Abstract][Full Text] [Related]
7. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases.
Yagami A; Furue M; Togawa M; Saito A; Hide M
J Dermatol; 2017 Apr; 44(4):375-385. PubMed ID: 27862227
[TBL] [Abstract][Full Text] [Related]
8. An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria.
Jáuregui I; García-Lirio E; Soriano AM; Gamboa PM; Antépara I
Expert Rev Clin Immunol; 2012 Jan; 8(1):33-41. PubMed ID: 22149338
[TBL] [Abstract][Full Text] [Related]
9. Bilastine: a new H
Church MK; Labeaga L
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1447-1452. PubMed ID: 28467671
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study.
Hide M; Yagami A; Togawa M; Saito A; Furue M
Allergol Int; 2017 Apr; 66(2):317-325. PubMed ID: 27599913
[TBL] [Abstract][Full Text] [Related]
11. Bilastine for the relief of allergy symptoms.
Sádaba Díaz de Rada B; Azanza Perea JR; Gomez-Guiu Hormigos A
Drugs Today (Barc); 2011 Apr; 47(4):251-62. PubMed ID: 21573249
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
[TBL] [Abstract][Full Text] [Related]
13. Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria.
Wolthers OD
Biomed Res Int; 2013; 2013():626837. PubMed ID: 23956994
[TBL] [Abstract][Full Text] [Related]
14. Bilastine and the central nervous system.
Montoro J; Mullol J; Dávila I; Ferrer M; Sastre J; Bartra J; Jáuregui I; del Cuvillo A; Valero A
J Investig Allergol Clin Immunol; 2011; 21 Suppl 3():9-15. PubMed ID: 22185045
[TBL] [Abstract][Full Text] [Related]
15. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis.
Tyl B; Kabbaj M; Azzam S; Sologuren A; Valiente R; Reinbolt E; Roupe K; Blanco N; Wheeler W
J Clin Pharmacol; 2012 Jun; 52(6):893-903. PubMed ID: 21642470
[TBL] [Abstract][Full Text] [Related]
16. Model-informed pediatric development applied to bilastine: Analysis of the clinical PK data and confirmation of the dose selected for the target population.
Vozmediano V; Lukas JC; Encinas E; Schmidt S; Sologuren A; Valiente R; Labeaga L; Campo C; Rodriguez M
Eur J Pharm Sci; 2019 Feb; 128():180-192. PubMed ID: 30468868
[TBL] [Abstract][Full Text] [Related]
17. Cognitive Performance Effects of Bilastine 20 mg During 6 Hours at 8000 ft Cabin Altitude.
Valk PJ; Simons R; Jetten AM; Valiente R; Labeaga L
Aerosp Med Hum Perform; 2016 Jul; 87(7):622-7. PubMed ID: 27503042
[TBL] [Abstract][Full Text] [Related]
18. Oral availability of bilastine.
Sádaba B; Gómez-Guiu A; Azanza JR; Ortega I; Valiente R
Clin Drug Investig; 2013 May; 33(5):375-81. PubMed ID: 23529786
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study.
Kuna P; Bachert C; Nowacki Z; van Cauwenberge P; Agache I; Fouquert L; Roger A; Sologuren A; Valiente R;
Clin Exp Allergy; 2009 Sep; 39(9):1338-47. PubMed ID: 19438584
[TBL] [Abstract][Full Text] [Related]
20. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers.
Conen S; Theunissen EL; Van Oers AC; Valiente R; Ramaekers JG
J Psychopharmacol; 2011 Nov; 25(11):1517-23. PubMed ID: 20855350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
